Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Azenosertib - Zentalis Pharmaceuticals

Next Previous
Drug Profile

Azenosertib - Zentalis Pharmaceuticals

Alternative Names: KP-2638; ZN-c3

Latest Information Update: 18 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zentalis Pharmaceuticals
  • Developer GSK; K-Group Beta; Zentalis Pharmaceuticals; Zentera Therapeutics
  • Class Amines; Antineoplastics; Cyclopentanes; Piperazines; Pyrazoles; Pyridines; Pyrimidinones; Small molecules
  • Mechanism of Action WEE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Osteosarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ovarian cancer
  • Phase II Pancreatic cancer; Solid tumours; Uterine cancer
  • Phase I/II Acute myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Osteosarcoma; Peritoneal cancer; Triple negative breast cancer
  • Phase I Breast cancer

Most Recent Events

  • 07 Aug 2026 Zentalis Pharmaceuticals met with the US FDA for the accelerated approval of azenosertib for Solid tumours
  • 03 Jun 2026 Azenosertib is still in phase I development for Solid tumours (Combination therapy) in USA, Australia, Bulgaria, Georgia, Serbia, South Korea and Bosnia-Herzegovina (PO) (NCT04516447)
  • 29 May 2026 Efficacy and adverse events data from a phase Ib MUIR trial in Solid tumours presented at the 62nd Annual Meeting of the American Society of Clinical Oncology (ASCO-2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top